Abstract
Central nervous system (CNS) prophylaxis is required during initial treatment of non-Hodgkin lymphoma (NHL) subtypes that carry a high risk of CNS involvement. Intrathecal (IT) liposomal cytarabine, a formulation with prolonged half-life, has been shown to be safe and effective in the treatment of meningeal disease in patients with high-grade lymphoma. We retrospectively reviewed all adult patients with high-grade NHL that received prophylactic therapy with IT liposomal cytarabine and developed neurologic complications in our institution between April 2007 and May 2009. We recorded information on hospital admission, chemotherapy regimens, clinical features, neuroimaging, cerebrospinal fluid, neurophysiology data, and outcome. Neurotoxicity was graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC). Four of fourteen patients (28%) developed moderate or severe neurotoxicity (grades 2 and 3 of the NCI-CTC), manifested as conus medullaris/cauda equine syndrome or pseudotumour cerebri-like syndrome, after a median of 3.5 IT courses of liposomal cytarabine. All patients had received corticosteroids to prevent arachnoiditis. Liposomal cytarabine given via the IT route, even with concomitant corticosteroid administration, can result in significant neurotoxicity in some patients. We discuss the potential pathogenesis of these effects and suggest hypothetical therapeutic measures to prevent these complications. Specialists should be aware of these possible complications when administering prophylactic IT liposomal cytarabine in high-grade NHL patients, and additional prospective studies should be conducted to more clearly delineate the frequency and characteristics of these complications.
Similar content being viewed by others
References
McClune B, Buadi F, Aslam N, Przepiorka D (2007) Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma. Leuk Lymphoma 48:1849–1851
Garcia-Marco JA, Panizo C, Garcia ES et al (2009) Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer 115:1892–1898
Sancho JM, Morgades M, Alonso N et al (2008) Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin’s lymphoma in Spain. Med Clin 131:441–446
Chamberlain MC, Nolan C, Abrey LE (2005) Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. J Neurooncol 75:71–83
Glantz MJ, LaFollette S, Jaeckle KA et al (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110–3116
Kim S, Chatelut E, Kim JC et al (1993) Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 11:2186–2193
Jabbour E, O’Brien S, Kantarjian H et al (2007) Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high dose methotrexate and cytarabine to patients with acute lymphoblastic leukemia. Blood 109:3214–3218
Hilgendorf I, Wolff D, Junghanss C et al (2008) Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation. Ann Hematol 87:1009–1012
Sommer C, Lackner H, Benesch M et al (2008) Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia. Ann Hematol 87:887–890
Kerr JZ, Berg S, Blaney SM (2001) Intrathecal chemotherapy. Crit Rev Oncol Hematol 37:227–236
Pui CH, Thiel E (2009) Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol 36:2–16
Brazis PW, Masdeu JC, Biller J (2007) Localization in clinical neurology. Lippincott Williams & Wilkins, Philadelphia
Spina M, Chimienti E, Martellotta F et al (2010) Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 116:1495–1501
Boyd K, Jenner M, Treleaven J, Kenny J, Rhoades E (2009) Liposomal cytarabine in cerebrospinal fluid. Br J Haematol 145:679
Acknowledgments
The authors acknowledge Dr M. Riverol and Dr P. Pastor for their assistance with the cases.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
J. Gállego Pérez-Larraya and J.A. Palma contributed equally to this work.
Rights and permissions
About this article
Cite this article
Gállego Pérez-Larraya, J., Palma, J.A., Carmona-Iragui, M. et al. Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma. J Neurooncol 103, 603–609 (2011). https://doi.org/10.1007/s11060-010-0428-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-010-0428-x